 CAMBRIDGE, Mass., Sept. 22, 2022 GLOBE NEWSWIRE -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following upcoming investor conferences: 